<SEC-DOCUMENT>0001075880-13-000055.txt : 20130807
<SEC-HEADER>0001075880-13-000055.hdr.sgml : 20130807
<ACCEPTANCE-DATETIME>20130806200042
ACCESSION NUMBER:		0001075880-13-000055
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130807
FILED AS OF DATE:		20130807
DATE AS OF CHANGE:		20130806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		131014845

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>aaform6kproforma.htm
<DESCRIPTION>CONVERTED BY EDGARWIZ
<TEXT>
<HTML>
<head><title>Converted by EDGARwiz</title> </head> <body style="FONT-SIZE:10pt; FONT-FAMILY:Times New Roman; COLOR:#000000; MARGIN-TOP:0px"> <div style=WIDTH:601px> <p style="PADDING-LEFT:56px; MARGIN:0px; LINE-HEIGHT:12pt" align=center><b>UNITED STATES </b></p> <p style="PADDING-LEFT:56px; MARGIN:0px; LINE-HEIGHT:12pt" align=center><b>SECURITIES AND EXCHANGE COMMISSION </b></p> <p style="PADDING-LEFT:56px; MARGIN:0px; LINE-HEIGHT:12pt" align=center><b>Washington, D.C. 20549 </b></p> <p style="PADDING-LEFT:56px; MARGIN:0px; TEXT-INDENT:-56px" align=justify>&nbsp;</p> <p style="MARGIN-BOTTOM:16px; FONT-SIZE:14pt; PADDING-LEFT:56px; MARGIN-TOP:0px" align=center><b>Form 6-K </b></p> <p style="MARGIN-BOTTOM:14px; FONT-SIZE:11.5pt; PADDING-LEFT:56px; MARGIN-TOP:0px; LINE-HEIGHT:14.4pt" align=center><b>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 </b></p> <p style="PADDING-LEFT:56px; MARGIN:0px; LINE-HEIGHT:12pt; TEXT-INDENT:-56px" align=left>For the month of August, 2013. </p> <p style="PADDING-LEFT:56px; MARGIN:0px; LINE-HEIGHT:12pt; TEXT-INDENT:-56px" align=justify>Commission File Number ________________ </p> <p style="MARGIN:0px; LINE-HEIGHT:12pt" align=center><br></p> <p style="FONT-SIZE:20pt; PADDING-LEFT:56px; MARGIN:0px; LINE-HEIGHT:12pt" align=center><b>Novogen Limited</b></p> <p style="PADDING-LEFT:56px; MARGIN:0px; LINE-HEIGHT:12pt" align=center>(Translation of registrant<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s name into English) </p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:12pt; PADDING-LEFT:56px; MARGIN:0px" align=center>1-7 Waterloo Road, Macquarie Park, NSW, Australia</p> <p style="MARGIN-BOTTOM:13px; PADDING-LEFT:56px; MARGIN-TOP:0px; LINE-HEIGHT:12pt" align=center>(Address of principal executive office) </p> <p style="PADDING-LEFT:56px; MARGIN:0px; LINE-HEIGHT:13.55pt; PADDING-RIGHT:71px; TEXT-INDENT:-56px" align=left>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</p> <table style="FONT-SIZE:10pt; MARGIN-TOP:0px" cellpadding=0 cellspacing=0> <tr style=FONT-SIZE:0px> <td width=585 /> </tr><tr> <td width=585 style=MARGIN-TOP:0px valign=top> <p style="PADDING-LEFT:56px; MARGIN:0px; TEXT-INDENT:-56px" align=justify>&nbsp;Form 20-F<font style=FONT-FAMILY:Wingdings> </font><font style=FONT-FAMILY:Wingdings><font face=Wingdings>x</font>&nbsp;</font><font style="FONT-FAMILY:Wingdings 2">&nbsp;</font>Form 40-F<font style=FONT-FAMILY:Wingdings> </font><font face=Wingdings>o</font></p></td></tr></table> <p style="PADDING-LEFT:56px; MARGIN:0px; LINE-HEIGHT:13.55pt; PADDING-RIGHT:71px; TEXT-INDENT:-56px" align=justify><b>&nbsp;</b>&nbsp;</p> <p style="MARGIN-BOTTOM:13px; PADDING-LEFT:56px; MARGIN-TOP:0px; LINE-HEIGHT:12pt; TEXT-INDENT:-56px" align=justify>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): <font face=Wingdings>o</font></p> <p style="MARGIN-BOTTOM:13px; PADDING-LEFT:56px; MARGIN-TOP:0px; LINE-HEIGHT:12pt; TEXT-INDENT:-56px" align=justify><b>Note</b>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders. </p> <p style="MARGIN-BOTTOM:13px; PADDING-LEFT:56px; MARGIN-TOP:0px; LINE-HEIGHT:12pt; TEXT-INDENT:-56px" align=justify>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<font face=Wingdings>o</font></p> <p style="MARGIN-BOTTOM:13px; PADDING-LEFT:56px; MARGIN-TOP:0px; LINE-HEIGHT:12pt; TEXT-INDENT:-56px" align=justify><b>Note</b>: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>home country<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font>), or under the rules of the home country exchange on which the registrant<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#146;</font>s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </p> <p style="MARGIN-BOTTOM:13px; PADDING-LEFT:56px; MARGIN-TOP:0px; LINE-HEIGHT:12pt; TEXT-INDENT:-56px" align=justify>Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. &nbsp;Yes&nbsp;&nbsp;<font style="FONT-FAMILY:Wingdings 2"><font face=Wingdings>o</font>&nbsp;</font>No <font face=Wingdings>x</font></p> <p style="PADDING-LEFT:56px; MARGIN:0px; TEXT-INDENT:-56px" align=justify>If <font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#147;</font>yes<font style="FONT-FAMILY:Arial Unicode MS,Times New Roman">&#148;</font> is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)</p> <p style="MARGIN:0px; LINE-HEIGHT:12pt" align=center><br></p> <p style="PADDING-LEFT:56px; MARGIN:0px; LINE-HEIGHT:12pt" align=center><b>SIGNATURES </b></p> <p style="MARGIN-BOTTOM:13px; PADDING-LEFT:56px; MARGIN-TOP:0px; LINE-HEIGHT:12pt; TEXT-INDENT:-56px" align=justify><b>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf</b> by the undersigned, thereunto duly authorized. </p> <p style="MARGIN-BOTTOM:13px; PADDING-LEFT:56px; MARGIN-TOP:0px; LINE-HEIGHT:12pt; PADDING-RIGHT:20px; TEXT-INDENT:-56px" align=justify><b>Novogen Limited</b> (Registrant) </p> <p style="PADDING-LEFT:56px; MARGIN:0px; TEXT-INDENT:-56px" align=justify>&nbsp;</p> <p style="PADDING-LEFT:56px; MARGIN:0px; TEXT-INDENT:-56px" align=justify>(Signature) *</p> <p style="PADDING-LEFT:56px; MARGIN:0px; TEXT-INDENT:-56px" align=justify>Andrew Bursill</p> <p style="PADDING-LEFT:56px; MARGIN:0px; TEXT-INDENT:-56px" align=justify>&nbsp;</p> <p style="PADDING-LEFT:56px; MARGIN:0px; TEXT-INDENT:-56px" align=justify>Date&nbsp;7 August 2013</p> <p style=MARGIN:0px align=justify><br></p> <p style="FONT-SIZE:9pt; FONT-FAMILY:ClassGarmnd BT,Times New Roman; PADDING-LEFT:56px; MARGIN:0px; TEXT-INDENT:-56px" align=justify>* Print the name and title under the signature of the signing officer.</p> <p style=MARGIN:0px align=justify><br><br></p></div></body>
<!-- EDGAR Validation Code: 9FE87525 -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>novogenannouncesestablishmen.htm
<DESCRIPTION>CONVERTED BY EDGARWIZ
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>Converted by EDGARwiz</TITLE>
</HEAD>
<BODY style="margin-top:0;font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:625.267px"><P style="margin-top:56.733px; margin-bottom:0px"><img src="novogenannouncesestablish001.jpg" alt="[novogenannouncesestablish001.jpg]" align=bottom height=70 width=550></P>
<P style="margin-top:23.2px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt"><B>ASX RELEASE</B></P>
<P style="margin-top:40.333px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt"><B>7 August 2013</B></P>
<P style="margin-top:21.6px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt"><B>Novogen Announces Appointment of Chairman of its Medical Advisory</B></P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt"><B>Board</B></P>
<P style="margin-top:21.467px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Novogen<FONT style="font-size:10.2pt"> &nbsp;&nbsp;</FONT>today<FONT style="font-size:10.1pt"> &nbsp;&nbsp;</FONT>announces<FONT style="font-size:10.2pt"> &nbsp;&nbsp;</FONT>the<FONT style="font-size:10.2pt"> &nbsp;&nbsp;</FONT>appointment<FONT style="font-size:10.05pt"> &nbsp;&nbsp;</FONT>of<FONT style="font-size:10.05pt"> &nbsp;&nbsp;</FONT>Professor<FONT style="font-size:10.1pt"> &nbsp;&nbsp;</FONT>Paul<FONT style="font-size:10.1pt"> &nbsp;&nbsp;</FONT>de<FONT style="font-size:10.2pt"> &nbsp;&nbsp;</FONT>Souza<FONT style="font-size:10.2pt"> &nbsp;&nbsp;</FONT>as</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Chairman of its Medical Advisory Board.</P>
<P style="margin-top:21.667px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">The<FONT style="font-size:6.75pt"> &nbsp;</FONT>purpose<FONT style="font-size:6.8pt"> &nbsp;</FONT>of<FONT style="font-size:6.65pt"> &nbsp;</FONT>the<FONT style="font-size:6.8pt"> &nbsp;</FONT>Board<FONT style="font-size:6.65pt"> &nbsp;</FONT>is<FONT style="font-size:6.8pt"> &nbsp;</FONT>to<FONT style="font-size:6.8pt"> &nbsp;</FONT>advise<FONT style="font-size:6.85pt"> &nbsp;</FONT>the<FONT style="font-size:6.8pt"> &nbsp;</FONT>Company<FONT style="font-size:6.65pt"> &nbsp;</FONT>on<FONT style="font-size:6.8pt"> &nbsp;</FONT>the<FONT style="font-size:6.8pt"> &nbsp;</FONT>design<FONT style="font-size:6.8pt"> &nbsp;</FONT>and<FONT style="font-size:7.45pt"> &nbsp;</FONT>conduct<FONT style="font-size:6.8pt"> &nbsp;</FONT>of</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">its<FONT style="font-size:9.75pt"> &nbsp;</FONT>clinical<FONT style="font-size:9.75pt"> &nbsp;</FONT>trials.<FONT style="font-size:10.05pt"> &nbsp;</FONT>The<FONT style="font-size:9.75pt"> &nbsp;</FONT>membership<FONT style="font-size:9.85pt"> &nbsp;</FONT>of<FONT style="font-size:9.65pt"> &nbsp;</FONT>the<FONT style="font-size:9.8pt"> &nbsp;</FONT>Board<FONT style="font-size:9.6pt"> &nbsp;</FONT>will<FONT style="font-size:10pt"> &nbsp;</FONT>be<FONT style="font-size:9.8pt"> &nbsp;</FONT>honorary,<FONT style="font-size:9.9pt"> &nbsp;</FONT>enabling<FONT style="font-size:9.75pt"> &nbsp;</FONT>the</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">various members also to act as Clinical Trial Investigators where appropriate.</P>
<P style="margin-top:21.6px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Professor<FONT style="font-size:8.65pt"> &nbsp;&nbsp;</FONT>De<FONT style="font-size:8.85pt"> &nbsp;&nbsp;</FONT>Souza<FONT style="font-size:8.7pt"> &nbsp;&nbsp;</FONT>is<FONT style="font-size:8.9pt"> &nbsp;&nbsp;</FONT>the<FONT style="font-size:8.7pt"> &nbsp;&nbsp;</FONT>Foundation<FONT style="font-size:8.75pt"> &nbsp;&nbsp;</FONT>Professor<FONT style="font-size:8.6pt"> &nbsp;&nbsp;</FONT>of<FONT style="font-size:8.8pt"> &nbsp;&nbsp;</FONT>Medical<FONT style="font-size:8.65pt"> &nbsp;&nbsp;</FONT>Oncology<FONT style="font-size:8.6pt"> &nbsp;&nbsp;</FONT>at<FONT style="font-size:8.75pt"> &nbsp;&nbsp;</FONT>the</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">University &nbsp;of &nbsp;Western &nbsp;Sydney, &nbsp;Director &nbsp;of &nbsp;the &nbsp;Translational &nbsp;Cancer &nbsp;Research</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Unit<FONT style="font-size:8.55pt"> &nbsp;&nbsp;</FONT>of<FONT style="font-size:8.45pt"> &nbsp;&nbsp;</FONT>The<FONT style="font-size:8.5pt"> &nbsp;&nbsp;</FONT>Ingham<FONT style="font-size:8.5pt"> &nbsp;&nbsp;</FONT>Institute<FONT style="font-size:8.55pt"> &nbsp;&nbsp;</FONT>of<FONT style="font-size:8.45pt"> &nbsp;&nbsp;</FONT>Medical<FONT style="font-size:8.5pt"> &nbsp;&nbsp;</FONT>Research,<FONT style="font-size:8.6pt"> &nbsp;&nbsp;</FONT>Conjoint<FONT style="font-size:8.55pt"> &nbsp;&nbsp;</FONT>Professor<FONT style="font-size:8.4pt"> &nbsp;&nbsp;</FONT>in<FONT style="font-size:8.55pt"> &nbsp;&nbsp;</FONT>the</P>
<P style="margin-top:2.867px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Faculty<FONT style="font-size:7.2pt"> &nbsp;</FONT>of<FONT style="font-size:7.2pt"> &nbsp;</FONT>Medicine<FONT style="font-size:7.4pt"> &nbsp;</FONT>of<FONT style="font-size:7.2pt"> &nbsp;</FONT>the<FONT style="font-size:7.3pt"> &nbsp;</FONT>University<FONT style="font-size:7.2pt"> &nbsp;</FONT>of<FONT style="font-size:7.2pt"> &nbsp;</FONT>NSW,<FONT style="font-size:7.4pt"> &nbsp;</FONT>and<FONT style="font-size:7.25pt"> &nbsp;</FONT>Director<FONT style="font-size:7.4pt"> &nbsp;</FONT>of<FONT style="font-size:7.2pt"> &nbsp;</FONT>the<FONT style="font-size:7.65pt"> &nbsp;</FONT>Department<FONT style="font-size:7.4pt"> &nbsp;</FONT>of</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Medical Oncology at Liverpool Hospital.</P>
<P style="margin-top:21.467px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Other<FONT style="font-size:9.45pt"> &nbsp;</FONT>members<FONT style="font-size:9.5pt"> &nbsp;</FONT>of<FONT style="font-size:9.4pt"> &nbsp;</FONT>the<FONT style="font-size:9.55pt"> &nbsp;</FONT>Board<FONT style="font-size:9.6pt"> &nbsp;</FONT>yet<FONT style="font-size:9.65pt"> &nbsp;</FONT>to<FONT style="font-size:9.5pt"> &nbsp;</FONT>be<FONT style="font-size:9.55pt"> &nbsp;</FONT>appointed<FONT style="font-size:9.35pt"> &nbsp;</FONT>will<FONT style="font-size:9.75pt"> &nbsp;</FONT>comprise<FONT style="font-size:9.6pt"> &nbsp;</FONT>experts<FONT style="font-size:9.75pt"> &nbsp;</FONT>drawn</P>
<P style="margin-top:2.867px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">from Australia, USA and Europe.</P>
<P style="margin-top:21.467px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Novogen CEO, Dr Graham Kelly,<FONT style="font-size:6.6pt"> &nbsp;</FONT>said today, <font style='font-family:Arial Unicode MS,Times New Roman'>&#8220;</font>Professor de Souza<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>s appointment<FONT style="font-size:7.5pt"> &nbsp;</FONT>is</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">timely<FONT style="font-size:8.3pt"> &nbsp;</FONT>as<FONT style="font-size:8.45pt"> &nbsp;</FONT>we<FONT style="font-size:8.5pt"> &nbsp;</FONT>now<FONT style="font-size:8.4pt"> &nbsp;</FONT>stand<FONT style="font-size:8.25pt"> &nbsp;</FONT>on<FONT style="font-size:8.45pt"> &nbsp;</FONT>the<FONT style="font-size:8.45pt"> &nbsp;</FONT>verge<FONT style="font-size:8.45pt"> &nbsp;</FONT>of<FONT style="font-size:8.3pt"> &nbsp;</FONT>bringing<FONT style="font-size:8.55pt"> &nbsp;</FONT>CS-6<FONT style="font-size:8.3pt"> &nbsp;</FONT>into<FONT style="font-size:8.45pt"> &nbsp;</FONT>the<FONT style="font-size:8.55pt"> &nbsp;</FONT>clinic.<FONT style="font-size:8.4pt"> &nbsp;</FONT>With<FONT style="font-size:8.35pt"> &nbsp;</FONT>CS-6</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">continuing<FONT style="font-size:10.1pt"> &nbsp;&nbsp;</FONT>to<FONT style="font-size:10.15pt"> &nbsp;&nbsp;</FONT>meet<FONT style="font-size:10.2pt"> &nbsp;&nbsp;</FONT>its<FONT style="font-size:10.15pt"> &nbsp;&nbsp;</FONT>targets<FONT style="font-size:10.15pt"> &nbsp;&nbsp;</FONT>in<FONT style="font-size:10.2pt"> &nbsp;&nbsp;</FONT>its<FONT style="font-size:10.15pt"> &nbsp;&nbsp;</FONT>current<FONT style="font-size:10.2pt"> &nbsp;&nbsp;</FONT>pre-clinical<FONT style="font-size:10.15pt"> &nbsp;&nbsp;</FONT>program,<FONT style="font-size:10.2pt"> &nbsp;&nbsp;</FONT>we<FONT style="font-size:10.2pt"> &nbsp;&nbsp;</FONT>find</P>
<P style="margin-top:2.867px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">ourselves<FONT style="font-size:7.35pt"> &nbsp;</FONT>in<FONT style="font-size:7.4pt"> &nbsp;</FONT>a<FONT style="font-size:7.1pt"> &nbsp;</FONT>position<FONT style="font-size:6.8pt"> &nbsp;</FONT>of<FONT style="font-size:7.2pt"> &nbsp;</FONT>being<FONT style="font-size:7.25pt"> &nbsp;</FONT>able<FONT style="font-size:7.35pt"> &nbsp;</FONT>to<FONT style="font-size:7.05pt"> &nbsp;</FONT>bring<FONT style="font-size:7.2pt"> &nbsp;</FONT>the<FONT style="font-size:7.3pt"> &nbsp;</FONT>drug<FONT style="font-size:7.15pt"> &nbsp;</FONT>into<FONT style="font-size:7.35pt"> &nbsp;</FONT>the<FONT style="font-size:7.35pt"> &nbsp;</FONT>clinic<FONT style="font-size:7pt"> &nbsp;</FONT>earlier<FONT style="font-size:7.25pt"> &nbsp;</FONT>than</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">originally<FONT style="font-size:6.85pt"> &nbsp;</FONT>predicted.<FONT style="font-size:7.15pt"> &nbsp;</FONT>Professor<FONT style="font-size:6.95pt"> &nbsp;</FONT>de<FONT style="font-size:7.35pt"> &nbsp;</FONT>Souza<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>s<FONT style="font-size:7.3pt"> &nbsp;</FONT>considerable<FONT style="font-size:7.05pt"> &nbsp;</FONT>expertise<FONT style="font-size:7.1pt"> &nbsp;</FONT>in<FONT style="font-size:7.1pt"> &nbsp;</FONT>translational</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">research<FONT style="font-size:8.45pt"> &nbsp;&nbsp;</FONT>and<FONT style="font-size:8.4pt"> &nbsp;&nbsp;</FONT>clinical<FONT style="font-size:8.5pt"> &nbsp;&nbsp;</FONT>trial<FONT style="font-size:8.5pt"> &nbsp;&nbsp;</FONT>design<FONT style="font-size:8.55pt"> &nbsp;&nbsp;</FONT>will<FONT style="font-size:8.5pt"> &nbsp;&nbsp;</FONT>be &nbsp;invaluable<FONT style="font-size:8.5pt"> &nbsp;&nbsp;</FONT>in<FONT style="font-size:8.4pt"> &nbsp;&nbsp;</FONT>guiding<FONT style="font-size:8.45pt"> &nbsp;&nbsp;</FONT>the<FONT style="font-size:8.55pt"> &nbsp;&nbsp;</FONT>Company</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">through this next important step.<font style='font-family:Arial Unicode MS,Times New Roman'>&#8221;</font></P>
<P style="margin-top:21.6px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt"><font style='font-family:Arial Unicode MS,Times New Roman'>&#8220;</font>Our<FONT style="font-size:8.45pt"> &nbsp;&nbsp;</FONT>goal<FONT style="font-size:8.5pt"> &nbsp;&nbsp;</FONT>is<FONT style="font-size:8.55pt"> &nbsp;&nbsp;</FONT>to<FONT style="font-size:8.5pt"> &nbsp;&nbsp;</FONT>conduct<FONT style="font-size:8.5pt"> &nbsp;&nbsp;</FONT>a<FONT style="font-size:8.55pt"> &nbsp;&nbsp;</FONT>joint<FONT style="font-size:8.4pt"> &nbsp;&nbsp;</FONT>Phase<FONT style="font-size:8.55pt"> &nbsp;&nbsp;</FONT>1a/1b<FONT style="font-size:8.55pt"> &nbsp;&nbsp;</FONT>in<FONT style="font-size:8.55pt"> &nbsp;&nbsp;</FONT>Australia<FONT style="font-size:8.55pt"> &nbsp;&nbsp;</FONT>and<FONT style="font-size:8.4pt"> &nbsp;&nbsp;</FONT>Hong<FONT style="font-size:8.45pt"> &nbsp;&nbsp;</FONT>Kong<FONT style="font-size:8.45pt"> &nbsp;&nbsp;</FONT>in</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">patients<FONT style="font-size:10.05pt"> &nbsp;&nbsp;&nbsp;</FONT>with<FONT style="font-size:10pt"> &nbsp;&nbsp;&nbsp;</FONT>late-stage<FONT style="font-size:10.1pt"> &nbsp;&nbsp;&nbsp;</FONT>cancer<FONT style="font-size:10.05pt"> &nbsp;&nbsp;&nbsp;</FONT>with<FONT style="font-size:10.05pt"> &nbsp;&nbsp;&nbsp;</FONT>a<FONT style="font-size:10.1pt"> &nbsp;&nbsp;&nbsp;</FONT>focus<FONT style="font-size:10.05pt"> &nbsp;&nbsp;&nbsp;</FONT>on<FONT style="font-size:10.05pt"> &nbsp;&nbsp;&nbsp;</FONT>Temozolomide-resistant</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">glioblastoma &nbsp;multiforme &nbsp;and &nbsp;carboplatin-refractory &nbsp;ovarian<FONT style="font-size:8.4pt"> &nbsp;&nbsp;</FONT>cancer.<FONT style="font-size:8.6pt"> &nbsp;&nbsp;</FONT>Naturally</P>
<P style="margin-top:2.933px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">we<FONT style="font-size:7.65pt"> &nbsp;</FONT>will<FONT style="font-size:7.6pt"> &nbsp;</FONT>be<FONT style="font-size:7.65pt"> &nbsp;</FONT>applying<FONT style="font-size:7.75pt"> &nbsp;</FONT>to<FONT style="font-size:7.6pt"> &nbsp;</FONT>the<FONT style="font-size:7.65pt"> &nbsp;</FONT>FDA<FONT style="font-size:7.55pt"> &nbsp;</FONT>to<FONT style="font-size:7.6pt"> &nbsp;</FONT>conduct<FONT style="font-size:7.65pt"> &nbsp;</FONT>clinical<FONT style="font-size:7.6pt"> &nbsp;</FONT>studies<FONT style="font-size:7.6pt"> &nbsp;</FONT>in<FONT style="font-size:7.65pt"> &nbsp;</FONT>the<FONT style="font-size:7.65pt"> &nbsp;</FONT>US<FONT style="font-size:7.7pt"> &nbsp;</FONT>in<FONT style="font-size:7.4pt"> &nbsp;</FONT>2014,<FONT style="font-size:7.7pt"> &nbsp;</FONT>but</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">the<FONT style="font-size:6.8pt"> &nbsp;</FONT>strategy<FONT style="font-size:6.65pt"> &nbsp;</FONT>of<FONT style="font-size:6.9pt"> &nbsp;</FONT>conducting<FONT style="font-size:6.7pt"> &nbsp;</FONT>our<FONT style="font-size:7.1pt"> &nbsp;</FONT>inaugural<FONT style="font-size:7.1pt"> &nbsp;</FONT>Phase<FONT style="font-size:7.1pt"> &nbsp;</FONT>1<FONT style="font-size:6.8pt"> &nbsp;</FONT>clinical<FONT style="font-size:6.75pt"> &nbsp;</FONT>studies<FONT style="font-size:6.75pt"> &nbsp;</FONT>in<FONT style="font-size:7.1pt"> &nbsp;</FONT>Australia<FONT style="font-size:6.8pt"> &nbsp;</FONT>and</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Hong Kong affords considerable time and cost savings,<font style='font-family:Arial Unicode MS,Times New Roman'>&#8221;</font> Kelly added.</P>
<P style="margin-top:21.6px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt"><B>About Novogen</B></P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Novogen<FONT style="font-size:9.85pt"> &nbsp;&nbsp;</FONT>Ltd<FONT style="font-size:9.7pt"> &nbsp;&nbsp;</FONT>is<FONT style="font-size:9.8pt"> &nbsp;&nbsp;</FONT>a<FONT style="font-size:9.95pt"> &nbsp;&nbsp;</FONT>biotechnology<FONT style="font-size:9.7pt"> &nbsp;&nbsp;</FONT>company<FONT style="font-size:9.7pt"> &nbsp;&nbsp;</FONT>whose<FONT style="font-size:9.8pt"> &nbsp;&nbsp;</FONT>shares<FONT style="font-size:9.8pt"> &nbsp;&nbsp;</FONT>trade<FONT style="font-size:9.8pt"> &nbsp;&nbsp;</FONT>on<FONT style="font-size:9.8pt"> &nbsp;&nbsp;</FONT>both<FONT style="font-size:9.75pt"> &nbsp;&nbsp;</FONT>the</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Australian<FONT style="font-size:9.3pt"> &nbsp;</FONT>Stock<FONT style="font-size:9.1pt"> &nbsp;</FONT>Exchange<FONT style="font-size:9.2pt"> &nbsp;</FONT>(symbol<FONT style="font-size:9.45pt"> &nbsp;</FONT><font style='font-family:Arial Unicode MS,Times New Roman'>&#8216;</font>NRT<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>)<FONT style="font-size:9.15pt"> &nbsp;</FONT>and<FONT style="font-size:9.1pt"> &nbsp;</FONT>NASDAQ<FONT style="font-size:9.15pt"> &nbsp;</FONT>(symbol<FONT style="font-size:9.2pt"> &nbsp;</FONT><font style='font-family:Arial Unicode MS,Times New Roman'>&#8216;</font>NVGN<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>). &nbsp;&nbsp;The</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Company<FONT style="font-size:6.95pt"> &nbsp;</FONT>is<FONT style="font-size:7.1pt"> &nbsp;</FONT>based<FONT style="font-size:6.9pt"> &nbsp;</FONT>in<FONT style="font-size:7.1pt"> &nbsp;</FONT>Sydney,<FONT style="font-size:7.15pt"> &nbsp;</FONT>Australia<FONT style="font-size:7.1pt"> &nbsp;</FONT>and<FONT style="font-size:7.45pt"> &nbsp;</FONT>in<FONT style="font-size:7.1pt"> &nbsp;</FONT>Manhattan,<FONT style="font-size:7.15pt"> &nbsp;</FONT>USA,<FONT style="font-size:7.15pt"> &nbsp;</FONT>and<FONT style="font-size:7.3pt"> &nbsp;</FONT>is<FONT style="font-size:6.8pt"> &nbsp;</FONT>focused<FONT style="font-size:6.95pt"> &nbsp;</FONT>on</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">the<FONT style="font-size:9.1pt"> &nbsp;&nbsp;</FONT>development<FONT style="font-size:9.1pt"> &nbsp;&nbsp;</FONT>of<FONT style="font-size:9.1pt"> &nbsp;&nbsp;</FONT>novel<FONT style="font-size:9pt"> &nbsp;&nbsp;</FONT>anti-cancer<FONT style="font-size:9.05pt"> &nbsp;&nbsp;</FONT>drugs.<FONT style="font-size:9.1pt"> &nbsp;&nbsp;</FONT>The<FONT style="font-size:9.05pt"> &nbsp;&nbsp;</FONT>Company<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>s<FONT style="font-size:9.05pt"> &nbsp;&nbsp;</FONT>inaugural<FONT style="font-size:9.25pt"> &nbsp;&nbsp;</FONT>drug</P>
<P style="margin-top:2.867px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">candidate is CS-6, with a pipeline of related drugs in development.</P>
<P style="margin-top:2.867px; margin-bottom:0px"><BR>
<BR></P>
<P style="margin-top:61.267px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt; page-break-before:always"><B>About CS-6</B></P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">CS-6<FONT style="font-size:7.2pt"> &nbsp;</FONT>belongs<FONT style="font-size:7.25pt"> &nbsp;</FONT>to<FONT style="font-size:7.35pt"> &nbsp;</FONT>a<FONT style="font-size:7.1pt"> &nbsp;</FONT>new<FONT style="font-size:7.2pt"> &nbsp;</FONT>class<FONT style="font-size:7.35pt"> &nbsp;</FONT>of<FONT style="font-size:7.2pt"> &nbsp;</FONT>drug<FONT style="font-size:7.15pt"> &nbsp;</FONT>candidates<FONT style="font-size:7.85pt"> &nbsp;</FONT>that<FONT style="font-size:7.4pt"> &nbsp;</FONT>target<FONT style="font-size:7.4pt"> &nbsp;</FONT>a<FONT style="font-size:7.1pt"> &nbsp;</FONT>mutation<FONT style="font-size:7.35pt"> &nbsp;</FONT>concerned</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">with<FONT style="font-size:7pt"> &nbsp;</FONT>the<FONT style="font-size:7.1pt"> &nbsp;</FONT>bioenergetics<FONT style="font-size:7.05pt"> &nbsp;</FONT>of<FONT style="font-size:6.95pt"> &nbsp;</FONT>a<FONT style="font-size:7.1pt"> &nbsp;</FONT>cell<FONT style="font-size:7pt"> &nbsp;</FONT>and<FONT style="font-size:6.9pt"> &nbsp;</FONT>which<FONT style="font-size:6.95pt"> &nbsp;</FONT>Novogen<FONT style="font-size:7.1pt"> &nbsp;</FONT>believes<FONT style="font-size:7.05pt"> &nbsp;</FONT>to<FONT style="font-size:7.05pt"> &nbsp;</FONT>be<FONT style="font-size:7.1pt"> &nbsp;</FONT>a<FONT style="font-size:7.1pt"> &nbsp;</FONT>fundamental</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">and<FONT style="font-size:6.65pt"> &nbsp;</FONT>key<FONT style="font-size:6.7pt"> &nbsp;</FONT>part<FONT style="font-size:6.75pt"> &nbsp;</FONT>of<FONT style="font-size:6.65pt"> &nbsp;</FONT>carcinogenesis.<FONT style="font-size:6.85pt"> &nbsp;</FONT>Inhibition<FONT style="font-size:6.85pt"> &nbsp;</FONT>of<FONT style="font-size:6.65pt"> &nbsp;</FONT>this<FONT style="font-size:6.8pt"> &nbsp;</FONT>mutation<FONT style="font-size:6.8pt"> &nbsp;</FONT>provides<FONT style="font-size:6.8pt"> &nbsp;</FONT>the<FONT style="font-size:6.8pt"> &nbsp;</FONT>potential</P>
<P style="margin-top:2.867px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">to &nbsp;act &nbsp;against &nbsp;all &nbsp;forms &nbsp;of &nbsp;cancer, &nbsp;including &nbsp;both &nbsp;cancer &nbsp;stem &nbsp;cells &nbsp;and &nbsp;their</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">daughter cells, and against cells with multiple mechanisms of drug resistance.</P>
<P style="margin-top:21.467px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">CS-6<FONT style="font-size:8.7pt"> &nbsp;&nbsp;</FONT>shows<FONT style="font-size:8.7pt"> &nbsp;&nbsp;</FONT>broad<FONT style="font-size:8.6pt"> &nbsp;&nbsp;</FONT>anti-proliferative<FONT style="font-size:8.7pt"> &nbsp;&nbsp;</FONT>and<FONT style="font-size:8.6pt"> &nbsp;&nbsp;</FONT>cytotoxic<FONT style="font-size:8.7pt"> &nbsp;&nbsp;</FONT>activity<FONT style="font-size:8.65pt"> &nbsp;&nbsp;</FONT>against<FONT style="font-size:8.8pt"> &nbsp;&nbsp;</FONT>all<FONT style="font-size:8.7pt"> &nbsp;&nbsp;</FONT>human</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">cancer<FONT style="font-size:8.85pt"> &nbsp;</FONT>cells<FONT style="font-size:9pt"> &nbsp;</FONT>that<FONT style="font-size:9.05pt"> &nbsp;</FONT>is<FONT style="font-size:9pt"> &nbsp;</FONT>has<FONT style="font-size:9.2pt"> &nbsp;</FONT>been<FONT style="font-size:9pt"> &nbsp;</FONT>tested<FONT style="font-size:8.8pt"> &nbsp;</FONT>against<FONT style="font-size:9.45pt"> &nbsp;</FONT>and<FONT style="font-size:8.8pt"> &nbsp;</FONT>ovarian<FONT style="font-size:9.05pt"> &nbsp;</FONT>cancer<FONT style="font-size:9.1pt"> &nbsp;</FONT>stem<FONT style="font-size:9.15pt"> &nbsp;</FONT>cells.<FONT style="font-size:9.05pt"> &nbsp;</FONT>CS-6</P>
<P style="margin-top:2.867px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">also<FONT style="font-size:9.95pt"> &nbsp;&nbsp;</FONT>has<FONT style="font-size:9.95pt"> &nbsp;&nbsp;</FONT>been<FONT style="font-size:10pt"> &nbsp;&nbsp;</FONT>designed<FONT style="font-size:9.85pt"> &nbsp;&nbsp;</FONT>deliberately<FONT style="font-size:9.85pt"> &nbsp;&nbsp;</FONT>to<FONT style="font-size:10.15pt"> &nbsp;&nbsp;</FONT>meet<FONT style="font-size:10pt"> &nbsp;&nbsp;</FONT>the<FONT style="font-size:10pt"> &nbsp;&nbsp;</FONT>major<FONT style="font-size:9.85pt"> &nbsp;&nbsp;</FONT>known<FONT style="font-size:10.1pt"> &nbsp;&nbsp;</FONT>criteria<FONT style="font-size:10pt"> &nbsp;&nbsp;</FONT>for</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">crossing<FONT style="font-size:8.3pt"> &nbsp;</FONT>the<FONT style="font-size:8.45pt"> &nbsp;</FONT>blood-brain<FONT style="font-size:8.45pt"> &nbsp;</FONT>barrier,<FONT style="font-size:8.45pt"> &nbsp;</FONT>and<FONT style="font-size:8.25pt"> &nbsp;</FONT>for<FONT style="font-size:8.25pt"> &nbsp;</FONT>that<FONT style="font-size:8.5pt"> &nbsp;</FONT>reason<FONT style="font-size:8.45pt"> &nbsp;</FONT>is<FONT style="font-size:8.75pt"> &nbsp;</FONT>being<FONT style="font-size:8.35pt"> &nbsp;</FONT>developed<FONT style="font-size:8.45pt"> &nbsp;</FONT>for<FONT style="font-size:8.25pt"> &nbsp;</FONT>the</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">treatment of glioblastoma multiforme, the main form of primary brain cancer.</P>
<P style="margin-top:40.333px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Further information</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Contact Dr Graham Kelly, Chief Executive Officer.</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Tel: 61 2 9476 0344</P>
<P style="margin-top:2.867px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Fax: 61 2 9476 0388</P>
<P style="margin-top:2.733px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Mobile: (61) 0429 854 390</P>
<P style="margin-top:21.467px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">16-20 Edgeworth David Ave &nbsp;Hornsby &nbsp;NSW 2077 &nbsp;AUSTRALIA</P>
<P style="margin-top:2.867px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">PO Box 2333 Hornsby Westfield &nbsp;NSW &nbsp;1635 &nbsp;&nbsp;AUSTRALIA</P>
<P style="margin-top:21.467px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">E: Graham.Kelly@novogen.com</P>
<P style="margin-top:21.467px; margin-bottom:0px; font-family:Cambria,Times New Roman; font-size:12pt">Further information is available on the Company<font style='font-family:Arial Unicode MS,Times New Roman'>&#8217;</font>s web site, www.novogen.com</P>
<P style="margin-top:21.467px; margin-bottom:0px"><BR>
<BR></P>
</DIV></BODY>
<!-- EDGAR Validation Code: 1B0F272A -->
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>novogenannouncesestablish001.jpg
<DESCRIPTION>IMAGE
<TEXT>
begin 644 novogenannouncesestablish001.jpg
M_]C_X``02D9)1@`!`0$```````#_X0"N17AI9@``34T`*@````@``8=I``0`
M```!````&@```````9*&``<```!Z````+`````!53DE#3T1%``!#`%(`10!!
M`%0`3P!2`#H`(`!G`&0`+0!J`'``90!G`"``=@`Q`"X`,``@`"@`=0!S`&D`
M;@!G`"``20!*`$<`(`!*`%``10!'`"``=@`V`#(`*0`L`"``<0!U`&$`;`!I
M`'0`>0`@`#T`(``Y`#``"O_^`#Q#4D5!5$]2.B!G9"UJ<&5G('8Q+C`@*'5S
M:6YG($E*1R!*4$5'('8V,BDL('%U86QI='D@/2`Y,`H`_]L`0P`(!@8'!@4(
M!P<'"0D("@P4#0P+"PP9$A,/%!T:'QX=&AP<("0N)R`B+",<'"@W*2PP,30T
M-!\G.3TX,CPN,S0R_]L`0P$)"0D,"PP8#0T8,B$<(3(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R_\``$0@`@`/H
M`P$B``(1`0,1`?_$`!\```$%`0$!`0$!```````````!`@,$!08'"`D*"__$
M`+40``(!`P,"!`,%!00$```!?0$"`P`$$042(3%!!A-180<B<10R@9&A""-"
ML<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U155E=8
M65IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JR
ML[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY
M^O_$`!\!``,!`0$!`0$!`0$````````!`@,$!08'"`D*"__$`+41``(!`@0$
M`P0'!00$``$"=P`!`@,1!`4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)R
MT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H
M:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BY
MNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:``P#`0`"
M$0,1`#\`]_HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BD)P.E-
M4[E!(QF@!]%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`P\"L?PUJ@U;0+2Y)S)M,
M<O'1T)5OU4UL,.#7BO@GQ6/#?C'5=$OY`EE<7LFQFX$4NXCGT!`'TQ515T8U
M*O))7V9[92TP-FGU)L%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`G:@T57N+J*UA,L\B1H#@L[8'YT!UL6**J6NHVEX6%M<
M13;>6\MPV/RJWFD-IK<*6FY[U5@U&SNW*6US#,RC)".&(%,6Y<HIN[VI"W?M
M0`XT=JR[W7]*T]REUJ%M#(!G:\H!_*HK;Q3H=VVRWU2U=CT`E&:7,BU2FU=)
MFN>017S)XZL_L?CC686R0UP9>?\`;^;^M?3`?(R.]>$?&&P-KXPAO`"$N[93
MG/&Y3M/Z;?SK6D]3S\=!^SOV-OX;_$,@P:%K4QS]RUN7/7_88^OH:]?#9%?(
M>>_ZU[M\,?&K:W:_V3J$F=1M4^5R>9HQQD_[0XS^!JJD.J,L)B;^Y(])HIN?
M:ES6)Z0>]%4_[1LQ<BV-S")R<"/S!NSUZ5:W>U`VFMQWUI*J7>J6=@FZ[N8H
M5]9'`%9J^,?#SOL75[0M_P!=12ND4J<Y*Z3-ZEJO#<Q7,8DAD21&'#*V0:E!
MS3(::W'T4F>*:7`')%`#J*Q[GQ/HMFY2XU.UC<=5,HR/PH@\4Z'<L%BU6T=C
MT`E%+F1I[*I:]F;-%1)(L@!4@@]"#3F8*I9B`!U)-!G;4=16;_;VE=]1M!S_
M`,]E_P`:7^W=*_Z"-I_W^7_&BZ*Y)=C1HJG;:G97CLEM=0S,HR1'(&('X5/-
M/'!$TLKI'&HRS.<`?C3N*S3L2T53MM2L[MREO<PS,.2$D!(%6\TMP::W%I::
M>G/:JD&I6=S.T$-U!)(O5$D!8?A0))LNT444P"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`H[444`-KC/B<!_P`(1==_F3_T(5VE<9\3
MO^1)N_\`>3_T(5$_A9OA?XT?4\J\-ZI=>%=2L]6"_P"AW!9)`O\`&H.&_P"!
M#&:]_M;F*[MH[B!@\<BAE8'@@CBO+_#OAV/Q'\,VMP%6XCFE>!\?=?<?Y]*?
M\,O$4EO/+X<U#]W(C-Y"OU!!^9/PZC\:RIMQLF>AC8JMS2CO'?T/4I?]6P]J
M\A^$H`\0ZHP')AYX']\UZXY)4_2O)/A+_P`C#JG_`%Q'_H9K2?Q(Y*"_<U/D
M>OG`ZUY/XU\<WMUJ+:'H3.#O\IY8AEW?^XG^-=]XKU-])\,:A>QG$D<)V'_:
MZ#]:\]^$^BQSW5UJ\PW&']S$2/XCRS?7I^M*;N^4O"TXQIRK35[;>I8T7X4K
M,@N-;NY3*_S&*(]#_M,?F)_*KFI_"73I82VF7<]O,!\HD.]2?YC\#7I&.*,<
M=J?LHF3QM9RO<\5T/Q1JW@K6/[)UG?):*0'0G<8P?XT)ZK70_%K2UU;PC!JM
MOMD-FXDW@\&)^&(_\=/X5:^*6C177A\:DJ?O[-\[AU*,<,/US^%+\.ITUOP-
M+IMYB1(B]JZGNA'`_(X_"BG)PG8O&THXG#^VBK/9G@./6KFEZE<Z1J=OJ-FV
MV>W<.GH?8_49'XFK7B'1)_#FNW6F7'WHFRCXXD0_=;^GX&LFO0^)'Q[4J<O0
M^KM&U*#5])M-0MCF*XC$B\],]1^!XJQ=W"6MK+/(V%C0LQ/8"O,O@QK!N-(O
M=)D;)M9!+%SSL?J/^^@Q_P"!5N_$_5_[.\+26ZOMEO&\D8/(7JQ_[Y!KCJ>[
M<^CP?[]Q2ZG+?#ZV;Q!XUU#Q#/&"(V+H2/XFX7\E_G76>.O&8\.6Z6UKL;49
MU^3=TC7NYJ;X?:3_`&3X3MVD3;/<YGE'NW0?@H`KSFWC_P"$R^)LGV@E[9IV
M8CMY4?`'XX'_`'T:PNU%+JSU8QA5KRE)>[$N:#X'U/Q?C5M:OIDAE^9"XS(X
M]@>%7TXKJ)OA-H;6^R.:[CD'\?F[OT(Q^0KO%C5%4(`JCH`.*DQ5JFEN<U3&
MU7*\79=CPV[L?$'PWU&.6WN#)8R-A2`?+D_V67^%L>E>L>&]>MO$.CQ7]O\`
M*3Q)&3RC]Q4VMZ5!K&D75C<#='*A'/\`">Q'T/->7?"Z\GT_Q/=Z3*Q_>HV]
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MNO\`KDW\JIJR,>9SJ<S/$/`O@ZR\5&^^TSS0&WV;?)V\[MV<Y!]*[+_A3VD?
M]!&^_P#(?_Q%9WP?=8WU;<0,^5C/']^O53+&!]]?SK.$8M'H8O$5H56HLY;P
MOX$L?"][-=VUU<2O-&(V$NW&`<]E%6/'8_XHG5AU_<'M71A@RY7!'L:Y[QW_
M`,B3JW_7`U;24=#BISE.M&4M[GBNAWMYX<O;/7+:/,#2M"P'_+0#&Y3[X.17
MT!IU]!J=A#>6L@DAF0,K#N*\U\%:'#X@^'M]8R\%KIVC<#E'`4AA^-1_#O79
M]%UB;PSJ7R9E(B!/"2=U'LPY'XUE3;C9=ST<9%5^9KXH_D>LN,J?I7C'P^0?
M\+%OL`<>>>G_`$T->S%AL)]J\;^'W_)1;[_MX_\`1E7._,CFPB_=5+]CV@=*
M6D[4M:G`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`
M%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`AKC/B=_R)-U_O)_Z$*[/O7&?$[_D2;K_>3_T(5$_A9T87^-'U(OA8,^#E
M_P"N\O\`Z%7/?$G0)=/OXO$FG9C<.OG,@^ZX^Z_\@:Z'X5_\B<O_`%\2_P#H
M1KKKRSAOK.:VN(P\4J%&4]P:E1O!&\JSI8J4NES&\+^((_$7A]+Q!ME4;)HS
MU1QU']?QK@?A+_R,&J#_`*8C_P!#-4M.GN?A[XTDL;AF-A<$*6)X:,GY7^H)
MP:N?"4C_`(2#4\$%3%P1_OFL^:\DGN=,J/)2J2CL[-':?$B-I/!&H;<_*JL<
M>@8$UD_"21#X=NH\@NERV<>X!%=OJEE'J6F7-E*/W<\;(?Q%>,>%=6F\#^*I
M['4P5A<^5.?[I!^63_=QG\ZN>DTS'#_O<-*DM]SW2C.!5>*YBGB$L3JR,-P8
M'@CZU*S`+DD"MCS6FG8YSQU-%!X,U1Y!E3"4`]R<?SKF/@_$ZZ7J4A'R-.J@
M^X7G^8K*^)/BA-4GCT73SYT<;@S,G.^3H$7UP?Z5W_@S0VT+PS;6D@`N&'F3
MX_OMU'X<#\*Q^*I<]*2]CA.66\F9OQ!\&)XITE9+8*-2MP6@8\;QW4_7]*^>
MKB&6VF>">)XIHV*/&XPRD=1CUKZYQ[UY]\0/`$7B.`ZCIZ"+58T],"<?W6_V
MO0_A].NG.VY\]BL-SKFCN>=_">]-IXZAAW86ZB>)ORW?S6NG\5M_PE/Q'L]&
M0[H+<A)!V_O2?^.[1^->::'>/H?B2RO)XWC>SN%,L9X88.&4_J*]6^%MA)>W
M^I:_=#,LDA12?[Q.Y_Y@5GB%>21W90^2E.H^FAZ;L$=OM4`8&!7C'PVD%GXZ
MG@F&V1XY(@#_`'@VXC\A7MN.*\0\7V-UX2\;IK-HI\F:7[3&<X!8_?0^YY/T
M/UK"HK-,]'!2YE.GU:/;LCUIU8^B:[9Z_I\=W9R95OOH?O(W<$=C6OD5JG<X
M)1<79K4:Y&P_2O%/!O\`I'Q1EEC;*>;<OD#MG_Z]=WX[\6PZ%I3V\#AM1G0K
M$@/*`\;SZ#T]36!\)]#DB2YUF96`F_=0%NK*.2P]B?Y5E+WI)+H>CATZ6'G.
M771%;XP0MY^F2#E=LB#Z_*:]#\-3I=>&M-FC(VM;1].WRC(_I67X[T%]?\-R
M10KFZA/FPCN6`Y'XC(KCOAQXPBL`-"U%A"N\_9W;@`YY0^G/K[BCX9MA;VV%
M7+O$]=JO>7`M;*:X*EA$C/@=3@9J42*W0Y^E4M:/_$EO1ZP/_(UKT//BO>29
MB^$_&,7BM;DQ6DMO]G*@^8<YW9]/I6]JG_(+NO\`KDW\C7FGP;(VZKTY:+^3
M5Z5JG_(+N?\`KDW\JE.\;G15IJG7Y8GAO@WPI)XG:\$>H/9^1M^X"=V[=UY'
MI76'X37*\GQ!/_WP?_BJA^#W#ZMGC_4]O]^O5^#44X)HZ\7BZL:KBGH9?A_2
MVT31;;3WG:=H4VF5A@M5'QV/^*(U7_K@:Z'/8_C7/>.S_P`43JH_Z8&KDO=9
MP4I-UHM[W,/X2?\`(K7!_P"GM_Y+5#XG>&G*IXAL`4GAP)]G!P.C_5?Y5?\`
MA*N?"UQU_P"/M_Y+7=2PI/"\<J*Z.,,I&00>M*,;P2.BK6=+%.7F<WX,\2)X
MET!)78"[A_=W"XQSZ_0\?K7`_#W_`)*+??\`;?\`]&&H9$N/AUXY^3)TVXZ>
MAB)_FO\`GK4OPZ8/\0[UD(96$[`^JF3(/ZBLN;WDF=BHJ%.I./PM:'M/:EI.
MU+72>*%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!112&
M@!M<WXYTJ[UKPO/9V**\[E2H9MHX8'K72XHP"*35U8JG-PDI+H<MX"TB\T3P
MTMG?QHDXF=MJMN&":ZFC''6EP*$K*P3FYR<GU..\>>%O^$ATG?;KF^MOFA[;
MO5?Q_P`*P?AKX<U;1M5O9=1M&@22%0I+`Y.[/:O3<>M&W%0Z:<N8WCBZD:+H
M]&'%<MXK\&6?B>(.2(+R,?NYU'Z-ZBNKI.U6TGHS"G4E3ES1>IX[!H?CWPH3
M'IK_`&BW!^58R'7_`+Y;I^%.N8?B/XA5K>9'M(6&&"E8E/XC+5Z_M%+MK/V7
MFSL6.>[BK]['!^$_AU;:'.M_?.MS?#E<+A(S[#UKNQQ2XHYQUJU%+1'+5JRJ
MRYI,6D(X/2G4AZ51F>0_%'P1<7-[!K.C6,L\TK;+B&$9).,A_P!,'\/Q]!\*
MZ0-$\/6=CM(D2/,F>NYN3^IK;V\]:`*'J3!<J:6S%K+UK1+/7=/>SO8]\;<@
M]T/9E/8UJ8H(HWT9<9.+NCQ^;P'XH\-WS77A^],J]@K;'*]@P/#8J1M0^)=P
M@M_LK1GH9!$BD_B37K>*-G^<5G[/LSL^NMZRBF_0\JT3X8WEY>_;O$MT9"S;
MGA5RQ<_[3'M[?K7I\,,=O"L42*D:`*JJ,``=JFP!151BD85L1.L_>88R*X/Q
M9\.;36Y)+RR=+6\<YD!7,<IQ_$/7W^O%=[S28XIM)DTJLZ3O%GC<.G?$3PZ/
M)M#+-$/N[765?P#<BII&^)6K(T#PF*-UVL"L:`@_G7KVT>@H"C'05G[+S9U?
M7GNX*_H<3\/_``G>^&K>[:^DA:2<J0L1)VX]2?K76WT;S6,\:#+,A`&>IQ5K
M%+WZU:C96.6=64Y\[W/%]*\)>.]"\W^S5@M_.QOQ)&V<9QU'H36G]E^*&/\`
MCZC_`#B_^)KU3%+@5'LUM=G0\;*6KBON.%\+P^-H]8)UZ=)+'RV``*?>R,?=
M`]ZWO%=A<:GX8U"SM4#3S0E4!;`S6UCFC%6HV5C"59N:FDD<C\/-%OM!T&:U
MU"-(YFN&D`5]W!`_P-=?2;13L4TK*R)J3=23D]V<QXS\,KXDT1X5P+N+,D#X
MZ-Z?0]/R/:N+^'GAC6=*\3?:KZR,,/D,N[>#\V17K1Y_*FA<-FI=-.5S:GBI
MPINGT9)1115G,%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%
M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444
M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
%110!_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
